- Home
- EGY vs SAGE Comparison
EGY vs SAGE Comparison
Compare EGY & SAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGY
- SAGE
- Stock Information
- Founded
- EGY 1985
- SAGE 2010
- Country
- EGY United States
- SAGE United States
- Employees
- EGY N/A
- SAGE N/A
- Industry
- EGY Oil & Gas Production
- SAGE Biotechnology: Pharmaceutical Preparations
- Sector
- EGY Energy
- SAGE Health Care
- Exchange
- EGY Nasdaq
- SAGE Nasdaq
- Market Cap
- EGY 458.2M
- SAGE 444.1M
- IPO Year
- EGY N/A
- SAGE 2014
- Fundamental
- Price
- EGY $4.35
- SAGE $7.31
- Analyst Decision
- EGY Strong Buy
- SAGE Hold
- Analyst Count
- EGY 1
- SAGE 20
- Target Price
- EGY $8.00
- SAGE $10.67
- AVG Volume (30 Days)
- EGY 697.5K
- SAGE 1.8M
- Earning Date
- EGY 03-12-2025
- SAGE 02-11-2025
- Dividend Yield
- EGY 5.75%
- SAGE N/A
- EPS Growth
- EGY 170.05
- SAGE N/A
- EPS
- EGY 0.86
- SAGE N/A
- Revenue
- EGY $506,421,000.00
- SAGE $41,243,000.00
- Revenue This Year
- EGY $9.04
- SAGE $123.13
- Revenue Next Year
- EGY N/A
- SAGE $69.65
- P/E Ratio
- EGY $5.04
- SAGE N/A
- Revenue Growth
- EGY 25.82
- SAGE N/A
- 52 Week Low
- EGY $3.96
- SAGE $4.62
- 52 Week High
- EGY $7.51
- SAGE $23.22
- Technical
- Relative Strength Index (RSI)
- EGY 50.15
- SAGE 60.55
- Support Level
- EGY $4.28
- SAGE $7.00
- Resistance Level
- EGY $4.49
- SAGE $7.26
- Average True Range (ATR)
- EGY 0.11
- SAGE 0.19
- MACD
- EGY 0.04
- SAGE -0.06
- Stochastic Oscillator
- EGY 72.64
- SAGE 57.14
About EGY VAALCO Energy Inc.
VAALCO Energy Inc is an independent energy company operating in the United States. It is principally engaged in the acquisition, exploration, development, and production of crude oil and natural gas. The company operates through geographical segments namely Gabon, Egypt, Canada, Equatorial Guinea and Corporate and Other. The company generates maximum revenue from the Gabon segment.
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.